Medical imaging and radiology
Aidoc
Clinical AI platform for radiology and enterprise imaging workflows.
Last updated: June 5, 2026
Back to directoryLumineticsCore medical AI product profile
FDA De Novo-cleared autonomous diagnostic AI for detecting more-than-mild diabetic retinopathy in eligible adults with diabetes.
Medical imaging and radiology
Best fit
Primary-care or diabetes-care settings that need point-of-care diabetic eye exam workflows with defined referral instructions.
- Primary use case
- Autonomous AI diabetic retinopathy detection from retinal images at the point of care
- Audience
- Primary care, diabetes care, ophthalmology referral networks, and health systems
- Risk level
- High
- Pricing signal
- Provider deployment pricing; request current terms and reimbursement workflow.
- Official sources
- 4 official sources
Compare within workflow: Medical imaging and radiology · comparison shortlist · source index
Regulatory, privacy, evidence, and workflow lens
Product-specific review. These product-specific signals summarize what the cited sources imply before treating LumineticsCore as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Because this is positioned as autonomous diagnostic AI, match use exactly to the FDA-cleared indications, contraindications, trained operators, Topcon camera requirement, and required workflow. |
|---|---|
| Privacy | Review retinal-image capture, device connectivity, diagnostic-result hosting, storage, access controls, report delivery, referral communication, and patient-consent documentation. |
| Evidence | Monitor unreadable-image rates, false positives, false negatives, referral completion, and local prevalence instead of relying only on clearance status. |
| Workflow | Best suited to protocolized diabetic-eye-exam workflows with defined eligibility screening, patient instructions, referral routing, billing, and quality oversight. |
Where LumineticsCore fits
Digital Diagnostics describes LumineticsCore as an autonomous AI diagnostic system for more-than-mild diabetic retinopathy in adults with diabetes, with FDA De Novo clearance, device-specific indications, contraindications, warnings, camera requirements, and point-of-care workflow controls.
Not for: Full eye exams, use outside the cleared patient population, or diabetic-retinopathy diagnosis without trained operators and device-specific workflow controls.
What to verify before using LumineticsCore
- FDA De Novo authorization, indications for use, contraindications, and exact eligible patient population.
- Required camera, image-quality workflow, operator training, and referral process.
- How results are documented, billed, and communicated to patients and eye-care providers.
- Local performance monitoring for unreadable images, false positives, false negatives, and follow-up completion.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- www.digitaldiagnostics.com / products / eye-disease
- www.digitaldiagnostics.com / products / eye-disease
- www.digitaldiagnostics.com / newsroom / fda-permits-marketing-of-lumineticscore-formerly-known-as-idx-dr-for-automated-detection-of-diabetic-retinopathy-in-primary-care
- www.digitaldiagnostics.com / privacy-policy
Related medical AI products
Medical imaging and radiology
Viz.ai
AI-powered care coordination platform with imaging-driven alerts across therapeutic areas.
Medical imaging and radiology
Ferrum Health
Clinical AI governance and deployment platform for health systems adopting multiple imaging or clinical AI models.
Medical imaging and radiology
Blackford Platform
Enterprise medical imaging AI platform for evaluating, deploying, routing, and monitoring multiple radiology AI applications.